MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy. Comparison of Two-dimensional and Volumetric Techniques

Academic Radiology

Volumn 19, Issue 1, 2012, Pages 48-54

  Galizia, Mauricio Stanzione ^a   Töre, Hüseyin Gürkan ^a   Chalian, Hamid ^a   McCarthy, Robert ^a   Salem, Riad ^a   Yaghmai, Vahid ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Computed tomography (CT); EASL criteria; Hepatocellular carcinoma; Volumetry; WHO criteria

Indexed keywords

IOHEXOL; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIOEMBOLIZATION; REPRODUCIBILITY; RETROSPECTIVE STUDY; SOLID TUMOR; TISSUE NECROSIS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 82955187550     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2011.09.005     Document Type: Article

References (41)

1. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
2. Salem R., Hunter R.D. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review. Int J Radiat Oncol Biol Phys 2006, 66:S83-S88.
3. Rhee T.K., Naik N.K., Deng J., et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 2008, 19:1180-1186.
4. Memon K., Kulik L., Lewandowski R.J., et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011, 141:526-535.
5. Keil S., Behrendt F.F., Stanzel S., et al. Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semi-automated and manual measurement of RECIST and WHO criteria. Eur Radiol 2008, 18:2456-2465.
6. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
7. Nishino M., Jagannathan J.P., Ramaiya N.H., et al. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010, 195:281-289.
8. Forner A., Ayuso C., Varela M., et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009, 115:616-623.
9. Ibrahim S.M., Nikolaidis P., Miller F.H., et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 2009, 34:566-581.
10. Keppke A.L., Salem R., Reddy D., et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 2007, 188:768-775.
11. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
12. Spira D., Fenchel M., Lauer U.M., et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011, 18:89-96.
13. Kuhnigk J.M., Dicken V., Bornemann L., et al. Morphological segmentation and partial volume analysis for volumetry of solid pulmonary lesions in thoracic CT scans. IEEE Trans Med Imaging 2006, 25:417-434.
14. Moltz J.H., Bornemann L., Kuhnigk J.M., et al. Advanced segmentation techniques for lung nodules, liver metastases, and enlarged lymph nodes in CT scans. IEEE J Sel Top Signal Process 2009, 3:122-134.
15. Bornemann L., Kuhnigk J.M., Dicken V., et al. Informatics in radiology (infoRAD): new tools for computer assistance in thoracic CT part 2. Therapy monitoring of pulmonary metastases. Radiographics 2005, 25:841-848.
16. Bornemann L., Dicken V., Kuhnigk J.M., et al. OncoTREAT: a software assistant for cancer therapy monitoring. Int J CARS 2007, 1:231-242.
17. Monsky W.L., Garza A.S., Kim I., et al. Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy. Cardiovasc Intervent Radiol 2011, 34:306-318.
18. Sato K.T., Lewandowski R.J., Mulcahy M.F., et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology 2008, 247:507-515.
19. Salem R., Thurston K.G. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006, 17:1251-1278.
20. Dawson P. Multi-slice CT contrast enhancement regimens. Clin Radiol 2004, 59:1051-1060.
21. Laghi A. Multidetector CT (64slices) of the liver: examination techniques. Eur Radiol 2007, 17:675-683.
22. Fleischmann D., Kamaya A. Optimal vascular and parenchymal contrast enhancement: the current state of the art. Radiol Clin North Am 2009, 47:13-26.
23. Miller F.H., Butler R.S., Hoff F.L., et al. Using triphasic helical CT to detect focal hepatic lesions in patients with neoplasms. AJR Am J Roentgenol 1998, 171:643-649.
24. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60.
25. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
26. Suzuki C., Jacobsson H., Hatschek T., et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 2008, 28:329-344.
27. Bosniak M.A. The current radiological approach to renal cysts. Radiology 1986, 158:1-10.
28. Miller F.H., Keppke A.L., Reddy D., et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007, 188:776-783.
29. Lin L.I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989, 45:255-268.
30. Mantatzis M., Kakolyris S., Amarantidis K., et al. Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate?. Eur Radiol 2009, 19:1809-1816.
31. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
32. Tochetto S.M., Rezai P., Rezvani M., et al. Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET?. Radiology 2010, 255:164-172.
33. Yaghmai V., Miller F.H., Rezai P., et al. Response to treatment series: part 2, tumor response assessment-using new and conventional criteria. AJR Am J Roentgenol 2011, 197:18-27.
34. Gillmore R., Stuart S., Kirkwood A., et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol 2011, April 15. [Epub ahead of print].
35. Duke E., Deng J., Ibrahim S.M., et al. Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol 2010, 21:515-521.
36. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
37. Riaz A., Memon K., Miller F.H., et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 2011, 54:695-704.
38. Jaffe C.C. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006, 24:3245-3251.
39. Lu D.S., Yu N.C., Raman S.S., et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005, 234:954-960.
40. Herber S., Biesterfeld S., Franz U., et al. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Intervent Radiol 2008, 31:768-777.
41. Riaz A., Miller F.H., Kulik L.M., et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010, 303:1062-1069.